Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients

March 17, 2016 at 8:25 am

Clinical Infectious Diseases January 2000 V.30 N.1 P.14-18

Carol A. Kauffman, José A. Vazquez, Jack D. Sobel, Harry A. Gallis, David S. McKinsey, A. W. Karchmer, Alan M. Sugar, Patricia Kay Sharkey, Gilbert J. Wise, Richard Mangi, Ann Mosher, Jeannette Y. Lee, William E. Dismukes, and National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group

1University of Michigan and Veterans Affairs Medical Center, Ann Arbor, Michigan

2Wayne State University Medical Center, Detroit, Michigan

3Duke University Medical Center, Durham, North Carolina

4Infectious Diseases Associates of Kansas City, Kansas City, Missouri

5Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

6Boston University Medical School, Boston, Massachusetts

7University of Texas Health Science Center at San Antonio, San Antonio, Texas

8Maimonides Medical Center, Brooklyn, New York

9St. Raphael Medical Center, New Haven, Connecticut

10University of Alabama Medical Center, Birmingham, Alabama

Although fungal urinary tract infections are an increasing nosocomial problem, the significance of funguria is still not clear.

This multicenter prospective surveillance study of 861 patients was undertaken to define the epidemiology, management, and outcomes of funguria.

Diabetes mellitus was present in 39% of patients, urinary tract abnormalities in 37.7%, and malignancy in 22.2%; only 10.9% had no underlying illnesses. Concomitant nonfungal infections were present in 85%, 90% had received antimicrobial agents, and 83.2% had urinary tract drainage devices.

Candida albicans was found in 51.8% of patients and Candida glabrata in 15.6%. Microbiological and clinical outcomes were documented for 530 (61.6%) of the 861 patients.

No specific therapy for funguria was given to 155 patients, and the yeast cleared from the urine of 117 (75.5%) of them. Of the 116 patients who had a catheter removed as the only treatment, the funguria cleared in 41 (35.3%).

Antifungal therapy was given to 259 patients, eradicating funguria in 130 (50.2%). The rate of eradication with fluconazole was 45.5%, and with amphotericin B bladder irrigation it was 54.4%. Only 7 patients (1.3%) had documented candidemia.

The mortality rate was 19.8%, reflecting the multiple serious underlying illnesses found in these patients with funguria.



Entry filed under: Antimicoticos, Biología Molecular, Epidemiología, Health Care-Associated Infections, Infecciones micoticas, Infecciones nosocomiales, Infecciones urinarias, Metodos diagnosticos, Sepsis, Update.

BROTE DE ENCEFALITIS DE SAN LUIS EN EL AREA METROPOLITANA BUENOS AIRES Limited Dissemination of Extended-Spectrum β-Lactamase– and Plasmid-Encoded AmpC–Producing Escherichia coli from Food and Farm Animals, Sweden


March 2016
« Feb   Apr »

Most Recent Posts

%d bloggers like this: